Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

NCT07053709 | Not Yet Recruiting

• 1 other identifier: 4-2025-300626
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD. The ultimate goal is to support the management of MAFLD and improve patients' quality of life by reducing both morbidity and mortality.

Conditions

Hyperuricemia and MAFLD

Outcome Measures

Primary Outcomes (1)

• Search for hyperuricemia in every patient with MAFLD

  1. Prevalence of Hyperuricemia in Patients with MAFLD Description:Number of participants diagnosed with hyperuricemia based on serum uric acid levels.Time Frame:At diagnosis and 6-month follow-up, Unit of Measure:Number of participants 2. Mean Serum Uric Acid Level Description:Average serum uric acid concentration among study participants. Time Frame:At diagnosis and 6-month follow-up, Unit of Measure:mg/dL 3. Alanine Aminotransferase (ALT) Level Description:Mean ALT level to assess liver function. Time Frame: At diagnosis and 6-month follow-up. Unit of Measure: IU/L 4. Aspartate Aminotransferase (AST) Level Description:Mean AST level to assess liver function.Time Frame:At diagnosis and 6-month follow-upUnit of Measure:IU/L 5. Alkaline Phosphatase (ALP) Level Description:Mean ALP level to assess liver function.Time Frame:At diagnosis and 6-month follow-up. Unit of Measure:IU/L 6. Serum Albumin Level:Mean serum albumin concentration.Time Frame:At diagnosis and 6-month follow up.

  At diagnosis and follow up after 6 month

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Adult patients with metabolic-associated fatty liver disease (MAFLD) were enrolled. Data collected included demographics, clinical history (comorbidities such as diabetes, hyperlipidemia, and hypertension), lifestyle factors (including alcohol intake), anthropometric measures (BMI, waist circumference), blood tests (uric acid, liver enzymes, lipid profile, CBC, HbA1c, hs-CRP, viral markers), and imaging by transient elastography (FibroScan with CAP).

You may qualify if:

• Adults aged over 18 years.
• Diagnosis of MAFLD based on abdominal ultrasonography or other validated imaging techniques.

You may not qualify if:

• Patients aged 18 years or younger.
• Pregnant individuals.
• Presence of any malignancy.
• Diagnosis of type 1 diabetes mellitus (T1DM).
• Patients with fatty liver disease who have previously undergone bariatric surgery.

Sponsors & Collaborators

• Assiut University: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples were collected to assess the following parameters: serum uric acid, liver function tests: albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP), lipid profile: total cholesterol, triglycerides, and high-density lipoprotein (HDL), complete blood count (CBC): hemoglobin (Hb), white blood cell count (WBC), and platelet count (PLT), viral markers: anti-HCV, HBsAg), plasma high-sensitivity C-reactive, protein, HbA1c.

MeSH Terms

Conditions

Hyperuricemia

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Assiut University

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Amira M Abdelmawgod, lecturer in Tropical Medicine, MD, Assuit University

CONTACT

+201012760437; amiramohmad60@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical lecturer

Study Record Dates

• First Submitted: June 21, 2025
• First Posted: July 8, 2025
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2027
• Last Updated: January 13, 2026

Record last verified: 2025-06